The ACMA has appointed Dr. Charles Stacey, President and CEO of Accera Pharmaceuticals to its Board of Governors. Dr. Stacey is the President and CEO of Accera, a global clinical stage biotechnology company focused on the development of therapeutics for CNS disease. Prior to joining Accera, he was with Inventages, the Nestlé backed venture capital and private equity group, with $1.5Bn under management. There he led the CNS interest as well as the fund’s interest in Asia. Prior to Inventages, Dr. Stacey ran a medical device company and worked for a number of early-stage healthcare companies.
Read Full Press Release: